Key points from article :
AstraZeneca will develop cardiovascular and catheter-based therapies.
Using Procella Therapeutics’ stem cell technology.
Therapies to repair damage caused by a heart attack.
Genetic markers identify engraftable human cardiac ventricular progenitor cells.
